Neuropeptide Y Y2 receptor and somatostatin sst2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells

British Journal of Pharmacology

Volumn 120, Issue 3, 1997, Pages 455-463

  Connor, Mark ^a,b   Yeo, Alison ^a   Henderson, Graeme ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Calcium mobilization; Intracellular calcium; Muscarinic receptors; Neuropeptide Y; SH SY5Y; Somatostatin

Indexed keywords

BIM 23027; CALCIUM ION; CARBACHOL; DEXTRO PHENYLALANYLPHENYLALANYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLPHENYLALANYL DEXTRO [3 (2 NAPHTHYL)ALANINAMIDE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FURA 2; L 362885; MAITOTOXIN; MUSCARINIC RECEPTOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; PERTUSSIS TOXIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; THAPSIGARGIN; UNCLASSIFIED DRUG; BORDETELLA VIRULENCE FACTOR; CALCIUM; CALCIUM CHANNEL; DELTA OPIATE RECEPTOR; HORMONE RECEPTOR; INOSINE TRIPHOSPHATE; MUSCARINIC AGENT; PEPTIDE YY RECEPTOR;

ARTICLE; CALCIUM CELL LEVEL; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; BRAIN TUMOR; CELL CULTURE; DRUG ANTAGONISM; DRUG POTENTIATION; ELECTROPHYSIOLOGY; METABOLISM; NEUROBLASTOMA;

BRAIN NEOPLASMS; CALCIUM; CALCIUM CHANNELS; CARBACHOL; ELECTROPHYSIOLOGY; HUMANS; INOSINE TRIPHOSPHATE; MUSCARINIC AGONISTS; NEUROBLASTOMA; NEUROPEPTIDE Y; PERTUSSIS TOXIN; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, OPIOID, DELTA; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TUMOR CELLS, CULTURED; VIRULENCE FACTORS, BORDETELLA;

EID: 0030614464     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700920     Document Type: Article

References (57)

1. AAKERLUND, L., GETHER, U., FUHLENDORFF, J., SCHWARTZ, T.W. & THASTRUP, O. (1990). Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett., 260, 73-78.
2. 2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells. FEBS Lett., 348, 192-196.
3. BARD, J.A., WALKER, M.J., BRANCHEK, T.A. & WEINSHANK, R.L. (1995). Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY. J. Biol. Chem., 45, 26762-26765.
4. -) cells. Br. J. Pharmacol., 117, 639-646.
5. CHESSEL, I.P., BLACK, M.D., FENIUK, W. & HUMPHREY, P.P.A. (1996). Operational characteristics of somatostatin receptors mediating inhibitory actions on rat locus coeruleus neurones. Br. J. Pharmacol., 117, 1673-1678.
6. CONNOR, M.A. & HENDERSON, G. (1996). δ and μ-Opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br. J. Pharmacol., 117, 333-340.
7. 2+ in SH-SY5Y cells when applied in the presence of carbachol. Br. J. Pharmacol., 117, 11P.
8. CONNOR, M.A., KEIR, M.J. & HENDERSON, G. (1995). Desensitization of δ opioid mobilization of intracellular calcium in SH-SY5Y cells. Br. J. Pharmacol., 116, 314P.
9. 2+ in the SH-SY5Y human neuroblastoma cell line. Br. J. Pharmacol., 118, 205-207.
10. 2+ and increases inositol phosphate production in human erythroleuke-mia cells. Biochem. Biophys. Res. Commun., 165, 1138-1144.
11. 2 receptor-mediated activation of L-type calcium channels. J. Cardiovasc. Pharmacol., 26, 721-728.
12. 3 receptor sub-type. Mol. Brain. Res., 26, 320-324.
13. EXTON, J.H. (1996). Regulation of phosphoinositide phospholipases by hormones, neurotransmitters and other agents linked to G proteins. Ann. Rev. Pharmacol. Toxicol., 36, 481-509.
14. FETH, F., RASCHER, W. & MICHEL, M.C. (1992). Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist. Br. J. Pharmacol., 105, 71-76.
15. 2+ current modulation during recovery of neuroblastoma cells from pertussis toxin pretreatment. FEBS Lett., 334, 322-326.
16. GERALD, C., WALKER, M.W., VAYSSE, P.J-J., HE, C., BRANCHEK, T.A. & WEINSHANK, R.L. (1995). Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem., 270, 26758-26761.
17. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
18. HEISLER, S., REISINE, T.D., HOOK, V.Y.H. & AXELROD, J. (1982). Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotrophin secretion in mouse pituitary tumor cells. Proc. Natl. Acad. Sci. U.S.A., 79, 6502-6506.
19. HOYER, D., LUBBERT, H. & BRUNS, C. (1994). Molecular pharmacology of somatostatin receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 441-453.
20. HOYER, D., BELL, G.I., BERELOWITZ, M., EPELBAUM, J., FENIUK, W., HUMPHREY, P.P.A., O'CARROLL, A.-M., PATEL, Y.C., SCHONBRUNN, A., TAYLOR, J.E. & REISINE, T. (1995a). Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci., 16, 86-88.
21. HOYER, D., PEREZ, J., SCHOEFFTER, P., LANGENEGGER, D., SCHUPBACH, E., KAUPMANN, K., LUBBERT, H., BRUNS, C. & REUBI, J.C. (1995b). Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors. Eur. J. Pharmacol., 289, 151-161.
22. 1 subtype pharmacology of a recombinantly expressed receptor. Mol. Pharmacol., 41, 817-821.
23. LACHOWICZ, A., PAWLIKOWSKI, M. & OCHEDALSKI, T. (1994). Somatostatin-14 increases the inositol-1,4,5-trisphosphate content in various areas of the brain. Biochem. Biophys. Res. Commun., 203, 379-384.
24. LARHAMMAR, D., BLOMQUIST, A.G., YEE, F., JAZIN, E., YOO, H. & WAHLESTEDT, C. (1992). Cloning and functional expression of a human neuropeptide Y/peplide YY receptor of the Y1 subtype. J. Biol. Chem., 267, 10935-10938.
25. LEWIS, D.L., WEIGHT, F.F. & LUINI, A. (1986). A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium current by somatostatin in a pituitary cell line. Proc. Natl. Acad. Sci. U.S.A., 83, 9035-9039.
26. 2 receptors in a human neuroblastoma cell line. J. Biol. Chem., 269, 8226-8233.
27. 2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. Neuropharmacology, 34, 1507-1514.
28. MCKEEN, E.S., FENIUK, W. & HUMPHREY, P.P.A. (1995). Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa. Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 402-411.
29. MIHARA, S., NORTH, R.A. & SUPRENANT, A. (1987). Somatostatin increases an inwardly rectifying potassium conductance in guinea pig submucous plexus neurones. J. Physiol., 390, 335-355.
30. 2+ increases in vascular smooth muscle cells. FEBS Lett., 259, 79-82.
31. 2+ concentration in cultured rat hippocampal neurones. Brain Res., 489, 361-364.
32. 2+ and inhibits adenylate cyclase in human erythroleukaemia cells. Am. J. Physiol., 355, E880-E885.
33. 2+ mobilization between bradykinin and agonists for pertussis toxin-sensitive G-protein coupled receptors in NG108-15 cells. FEBS Lett., 301, 223-226.
34. 2+ system through cross-talk between opioid receptors and P2-purinergic or bradykinin receptors in NG108-15 cells. Biochem. J., 290, 241-247.
35. PATEL, Y.C. & SRIKANT, C.B. (1994). Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology, 135, 2814-2817.
36. PERNEY, T.M. & MILLER, R.J. (1989). Two different G-proteins mediate neuropeptide Y and bradykinin-stimulated phospholipid breakdown in cultured rat sensory neurones. J. Biol. Chem., 264, 7317-7327.
37. 2+ in response to lysylbradykinin and histamine in a cultured human colonic epithelium. Eur. J. Pharmacol., 199, 77-91.
38. RAYNOR, K., MURPHY, W.A. COY, D.H., TAYLOR, J.E., MOREAU, J.-P., YASUDA, K., BELL, G.I. & REISINE, T. (1993a). Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol. Pharmacol., 43, 838-844.
39. RAYNOR, K., O'CARROLL, A.-M., KONG, H., YASUDA, K., MAHAN, L.C., BELL, G.I. & REISINE, T. (1993b). Characterization of cloned somatostatin receptors SRIFR4 and SRIFR5. Mol. Pharmacol., 44, 385-392.
40. REYNOLDS, E.E. & YOKOTA, S. (1988). Neuropeptide Y receptor-effector coupling mechanisms in cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 151, 919-925.
41. ROSE, P.M., FERNANDES, P., LYNCH, J.S., FRAZIER, S.T., FISHER, S.M., KODUKULA, K., KIENZLE, B. & SEETHALA, R. (1995). Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J. Biol. Chem., 270, 22661-22664.
42. 1 receptor antagonist. Eur. J. Pharmacol., 271, R11.
43. SEWARD, E., HAMMOND, C. & HENDERSON, G. (1991). μ-Opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc. R. Soc. Lond. (Series B), 244, 129-135.
44. SEWARD, E.P., HENDERSON, G. & SADEE, W. (1990). Inhibition of calcium currents by μ and δ opioid receptor activation in differentiated human neuroblastoma cells. Adv. Biosci., 75, 181-183.
45. SHIGERI, Y., MIHARA, S. & FUJIMOTO, M. (1991). Neuropeptide Y receptor in vascular smooth muscle. J. Neurochem., 56, 852-859.
46. 2+ concentration via phospholipase C-dependent pathway in porcine aortic smooth muscle cells. J. Biochem., 118, 515-520.
47. SHOEFFTER, P., PEREZ, J., LANGENEGGER, D., SCHUPBACH, E., BOBIRNAC, I., LUBBERT, H., BRUNS, C. & HOYER, D. (1995). Characterization and distribution of somatostatin SS-1 and SRIF-1 binding sites in rat brain: identity with SSTR-2 receptors. Eur. J. Pharmacol., 289, 163-173.
48. SOERGEL, D.G., YASUMOTO, T., DALY, J.W. & GUSOVSKY, F. (1992). Maitotoxin effects are blocked by SK&F 96365, an inhibitor of receptor-mediated calcium entry. Mol. Pharmacol., 41, 487-493.
49. TANG, W.-J. & GILMAN, A.G. (1991). Type specific regulation of adenylyl cyclase by G protein βγ subunits. Science, 254, 1500-1503.
50. 2+-ATPase. Proc. Natl. Acad. Sci. U.S.A., 87, 2466-2470.
51. 2+ mobilization in single cells of bradykinin-sensitized differentiated neuroblastoma hybridoma (NG108-15) cells. Neurosci. Lett., 148, 93-96.
52. VAUGHAN, P.F.T., PEERS, C. & WALKER, J.H. (1995). The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Gen. Pharmacol., 26, 1191-1201.
53. WAHLESTEDT, C. & REIS, D.J. (1993). Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol. Toxicol., 32, 309-352.
54. 2+ currents in rat sensory neurones. J. Neurosci., 8, 2438-2446.
55. WANG, H.-L., BOGEN, C., REISINE, T. & DICHTER, M. (1989). Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurones. Proc., Natl. Acad. Sci. U.S.A., 86, 9616-9620.
56. WESTLIND-DANIELSSON, A., UNDEN, A., ABENS, J., ANDELL, S. & BARTFAI, T. (1987). Neuropeptide Y receptors and the inhibition of adenylate cyclase in the human frontal and temporal cortex. Neurosci. Lett., 74, 237-242.
57. 2 somatostatin receptors. Br. J. Pharmacol., (in press).